Emily Rossi
Senior Scientist II, Quantitative Medicine & Genomics Abbvie
Seminars
Tuesday 21st July 2026
Building the ctDNA Blueprint: A Cross-Functional Strategy to Advance Oncology Drug Development
10:20 am
- ctDNA as a predictive marker for therapeutic response and a potential surrogate for survival outcomes, enabling faster, more efficient trial designs
- ctDNA as an early, sensitive marker for tracking tumor burden and minimal residual disease (MRD), allowing for earlier intervention and better monitoring of disease progression
- Longitudinal ctDNA analysis for determining biologically active dosages, allowing for adjustments in dosage regimens to maximize efficacy while minimizing toxicity
